1例信迪利单抗致免疫性心肌炎引发心力衰竭及呼吸衰竭的病例分析与药学监护  

Case Analysis and Pharmaceutical Care for a Case of Heart Failure and Respiratory Failure Caused by Immune-related Myocarditis Induced by Sintilimab

作　　者：周慧萍[1] 唐源 陈永春[1] 陈晓艳[1] 林文明 杨土泉 郑洪南 Zhou Huiping;Tang Yuan;Chen Yongchun;Chen Xiaoyan;Lin Wenming;Yang Tuquan;Zheng Hongnan(First Naval Hospital of Southern Theater Command,Guangdong Zhanjiang 524005,China)

机构地区：[1]中国人民解放军南部战区海军第一医院药剂科,广东湛江524005

出　　处：《中国药师》2022年第6期1036-1040,共5页China Pharmacist

基　　金：湛江市非资助科技攻关计划项目(编号:2021B01362)。

摘　　要：1例肝癌患者在使用信迪利单抗治疗过程中,出现胸痛、胸闷、阵发性呼吸困难等症状,结合患者既往病史、实验室检查结果等,考虑为免疫相关性心肌炎。临床药师参与了该患者的治疗过程,并结合相关文献分析不良反应发生的机制、梳理治疗过程,对治疗方案提出药学建议。经过临床药师与医师的密切合作,患者心功能逐渐恢复,病情好转出院。临床药师应参与到抗肿瘤药物的监测与管理中,为提升抗肿瘤药物治疗的安全性和有效性发挥作用。A patient with liver cancer developed symptoms such as chest pain, chest tightness and paroxysmal dyspnea during the treatment with sintilimab. According to the patient’s past medical history and laboratory findings, it was considered as immune-related myocarditis. Clinical pharmacists participated in the treatment process of the patient, analyzed the mechanism of adverse reactions in combination with relevant literature, combed the treatment process, and put forward pharmaceutical suggestions for the treatment scheme. After close cooperation between clinical pharmacists and physicians, the patient’s cardiac function gradually recovered. After the conditions were improved, the patient was discharged from the hospital. Clinical pharmacists should participate in the monitoring and management of antitumor drugs and play a role in improving the safety and effectiveness of antitumor drug treatment.

关 键 词：免疫相关性心肌炎 信迪利单抗 病例分析 药学监护 

分 类 号：R97[医药卫生—药品]